A Case of Hepatitis B Virus Reactivation in a HBsAg-Negative and Anti-HBs-Positive Patient with Diffuse Large B-Cell Lymphoma after Rituximab plus CHOP Chemotherapy
Soonchunhyang Medical Science
;
: 168-171, 2014.
Article
Dans Coréen
| WPRIM
| ID: wpr-95062
ABSTRACT
The reactivation of hepatitis B virus (HBV) is well known complication among lymphoma patient related with chemotherapy. Rituximab is monoclonal antibody that targets B-lymphocytes for treatment of lymphoma and it increases reactivation of HBV. Although most of reactivation occurs in HBV carrier, it can also rarely occur when hepatitis B surface antigen (HBsAg) is negative. Furthermore it is less frequently reported in lymphoma patient when HBV serology shows HBsAg is negative and anti-HBs is positive. We report a case of HBV reactivation following 6 cycle of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy for diffuse large B-cell lymphoma in HBsAg negative/anti-HBs positive 58-year-old male, with a review of the literature.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Vincristine
/
Lymphocytes B
/
Doxorubicine
/
Virus de l'hépatite B
/
Lymphome B
/
Traitement médicamenteux
/
Rituximab
/
Antigènes de surface du virus de l'hépatite B
/
Lymphomes
Limites du sujet:
Humains
/
Mâle
langue:
Coréen
Texte intégral:
Soonchunhyang Medical Science
Année:
2014
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS